Ixazomib Citrate in Treating Patients With Chronic Graft-versus-Host Disease
Status:
Completed
Trial end date:
2018-06-27
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well ixazomib citrate works in treating patients with chronic
graft-versus-host disease. Chronic graft-versus-host disease is a complication of a donor
bone marrow or blood cell transplant, usually occurring more than three months after
transplant, in which donor cells damage the host tissue. Ixazomib citrate may be an effective
treatment for chronic graft-versus-host disease.